Addiction medicine physician here. I want to validate what everyone is experiencing and add some clinical nuance.
We are very excited about GLP-1 RAs in the addiction medicine field. The preclinical data on alcohol, nicotine, and even opioid use reduction is compelling. The mechanism — modulation of mesolimbic dopamine — makes theoretical sense, as substance use disorders share overlapping neurocircuitry with compulsive overeating.
However, a few cautions:
- Do not abruptly stop alcohol if you are a heavy daily drinker. Alcohol withdrawal can be medically dangerous. Taper under medical supervision.
- If you find your alcohol use decreasing, use this as an opportunity to build non-chemical coping skills. Meditation, therapy, exercise, social connection.
- If you stop the GLP-1 medication, the reward-modulation effect may wane. Plan for this.
But overall — if you're drinking less and feeling good about it? That is a genuinely positive outcome, even if it wasn't the original intent of the prescription.
Last edited: Mar 1, 2026 at 9:47 AM